ReviewContraception2010
New frontiers in nonhormonal male contraception.
Review in Contraception, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Molecular basis of the higher-order assembly of CatSper.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Fertility Control in Wildlife: Review of Current Status, Including Novel and Future Technologies.Advances in experimental medicine and biology · 2026Review
- Traditional contraceptive practices: survey of medicinal plants used to control birth in four states in Nigeria.BMC complementary medicine and therapies · 2025Article
- Article
- Spermiation: Insights from Studies on the Adjudin Model.Advances in experimental medicine and biology · 2021Review
- The Na+ and K+ transport system of sperm (ATP1A4) is essential for male fertility and an attractive target for male contraception†.Biology of reproduction · 2020Review
- Design, Synthesis, and in Vitro and in Vivo Evaluation of Ouabain Analogues as Potent and Selective Na,K-ATPase α4 Isoform Inhibitors for Male Contraception.Journal of medicinal chemistry · 2018Article
- Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin.Current medicinal chemistry · 2016Review
- Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity.Current molecular pharmacology · 2014Review
- Adjudin disrupts spermatogenesis by targeting drug transporters: Lesson from the breast cancer resistance protein (BCRP).Spermatogenesis · 2013Article
- Microtubule affinity-regulating kinase 4 (MARK4) is a component of the ectoplasmic specialization in the rat testis.Spermatogenesis · 2012Article
- The apical ectoplasmic specialization-blood-testis barrier functional axis is a novel target for male contraception.Advances in experimental medicine and biology · 2012Article
- The blood-testis barrier and its implications for male contraception.Pharmacological reviews · 2012Review
- C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.Advances in experimental medicine and biology · 2012Article
- Contraceptive methods: needs, options and utilization.Journal of obstetrics and gynaecology of India · 2011Article
- Adjudin disrupts spermatogenesis via the action of some unlikely partners: Eps8, Arp2/3 complex, drebrin E, PAR6 and 14-3-3.Spermatogenesis · 2011Article
- Interactions of laminin β3 fragment with β1-integrin receptor: A revisit of the apical ectoplasmic specialization-blood-testis-barrier-hemidesmosome functional axis in the testis.Spermatogenesis · 2011Article
- A study to assess the assembly of a functional blood-testis barrier in developing rat testes.Spermatogenesis · 2011Article
- Testin and actin are key molecular targets of adjudin, an anti-spermatogenic agent, in the testis.Spermatogenesis · 2011Article
- Drug transporters, the blood-testis barrier, and spermatogenesis.The Journal of endocrinology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The world's population is nearing 6.8 billion, and we are in need of a male contraceptive that is safe, effective, reversible and affordable. Hormonal approaches, which employ different formulations of testosterone administered in combination with other hormones, have shown considerable promise in clinical trials, and they are currently at the forefront of research and development. However, the long-term effects of using hormones throughout a male's reproductive life for contraception are unknown, and it may take decades before this information becomes available. Because of this, many investigators are aiming to bring a nonhormonal male contraceptive to the consumer market. Indeed, there are several distinct but feasible avenues in which fertility can be regulated without affecting the hypothalamus-pituitary-testis axis. In this review, we discuss several approaches for fertility control involving the testis that one day may lead to the development of a nonhormonal male contraceptive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.